- Strategically positioned to be a global leader in the CBD space
- Expands CBD chocolate product line and provides accessibility to consumers in convenience stores across the U.S.
- Joint ventures globally in nutraceuticals, pharmaceuticals and medical device products
Earth Science Tech, Inc. (OTC: ETST) is a Florida-based biotechnology company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals and medical devices. The company operates through three wholly owned subsidiaries – Earth Science Pharmaceutical Inc., Cannabis Therapeutics Inc. and KannaBidioiD, Inc. – each of which are equally invested in developing the company’s role as a global leader in the CBD space. Last year, the company acquired Canna Inno Laboratories, Inc. as part of its strategic plan to expand into Canada and gain access to government grants.
By making its products more available to consumers through its association with AATAC, an advisory board that focuses on convenience stores, ETST is setting itself apart as a major provider of premium CBD products. Through a joint venture with Karmavore Superfoods, the company is expanding its unique full spectrum cannabinoid CBD raw dark chocolate line from two to five products. With the anticipated launch of three new CBD-based patent formulas – chocolate-covered mangoes, chocolate coconut peppermint cups and chocolate caramelized quinoa crunch – ETST and AATAC anticipate a high volume of preorders from approximately 90,000 retail outlets throughout the United States. These chocolates are scheduled to hit the market in the coming weeks. The move to provide this product in convenience stores provides ETST with the means to increase its consumer base across every sector of the population. In a news release (http://cnw.fm/9vW10) , Jill Buzan, chief sales officer of ETST, stated, “This could lead to huge exponential growth for ETST’s sales in the next few months.”
The expanded reach throughout the United States is not the company’s only focus. Its goal is to become a global leader in the CBD space, and ETST is taking promising steps in that direction.
In March, ETST announced that it had received a grant from the Government of Quebec to pursue the development of three CBD-based nutraceutical provisional patent products. These products include a neuron protector, a breast protector and a product designed to improve antioxidant ingestion.
Through a joint venture with Bionatus Laboratrio Botnico of Brazil and its Canadian division, Bionatus Botanical Laboratories, Inc., ETST has three products in various stages. Propovit’s purpose is to alleviate throat irritation, colds and bad breath, and it is enriched with ETST hemp oil. Bionatus is being reformulated with the addition of CBD to potentially enhance its anti-inflammatory and bronchial-dilation properties. A third product is in the planning stages, and details will be shared soon.
A pre-launch clinical study of ‘Hygee’ with Clinique Santé Amitié in Quebec, Canada, is currently being conducted. ‘Hygee’ is the name of ETST’s MSN-2 home testing medical kit designed for the detection of sexually transmitted infections (STI), such as chlamydia. This kit will be marketed worldwide, and the company anticipates approval of the trademark within the next nine to 10 months.
For more information, visit the company’s website at www.EarthScienceTech.com
More from CannabisNewsWire
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.cannabisnewswire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
